Protagonist Therapeutics
NASDAQ: PTGXMilpitas, US · Delaware corporation · 2 known investors
Founders & leadership
PF
Paul F. TruexDirector
AK
Asish K. Xavier, Ph.D.Director
MP
Michael Panaccio, Ph.D.Director
AS
Armen Shanafelt, Ph.D.Director
DV
Dinesh V. Patel, PhDExecutive Officer, Director
HE
Harold E. Selick, Ph.D.Director
Investors · 2
Competitors · 10
by search overlapPatSnap49 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Czytaj więcej45 shared keywords
Cowles_Investments_StemCentrx41 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Diabetes Prevention Program35 shared keywords
Seeking Alpha32 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
by Catepillar28 shared keywords
Robinhood28 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TipRanks27 shared keywordsFinancial analysis and stock research platform.
Thepharmaletter26 shared keywords
Thumbnail for Seragon Pharmaceuticals25 shared keywords
Companies competing with Protagonist Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$17.5MraisedJul 2015 · 9 investors · BiotechnologyRule 506(b)
▶$17.5MraisedJul 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul F. TruexDirector
- Asish K. Xavier, Ph.D.Director
- Michael Panaccio, Ph.D.Director
- Armen Shanafelt, Ph.D.Director
- Dinesh V. Patel, PhDExecutive Officer, Director
- Harold E. Selick, Ph.D.Director
- Offering amount
- $40M
- Amount sold
- $17.5M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $218.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $223.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.